April 4 (EPO), March 29 (WO)

Aberdeen Univ. WO 01/21800

VHSV antibodies

Aberdeen, UK

Monoclonal antibodies that neutralize viral hemorrhagic septicemia virus; for viral therapy.

Affina Immunotech. WO 01/21660

Combatting cardiomyopathy


Peptides for combating the autoantibodies responsible for dilative cardiomyopathy.

Al-Mahmood, S. WO 01/21831

Angioigenesis genes


Isolating mRNA from endothelial cells growing in cell culture; for identifying angiogenesis regulating genes.

Alabama, Univ. of WO 01/21216

Cell-targeted gene therapy

Birmingham, Ala.

Capsid-modified recombinant adenoviral vector having an introduced single-chain antibody for cell targeting.

Amgen WO 01/21812

MAP kinase phosphatases

Thousand Oaks, Calif.

Phosphatases that activate MAP kinase pathways, encoding genes, antibodies; for diagnostics and therapeutics.

An-Go-Gen WO 01/21184

Angiogenic therapy


Fibroblasts that express angiogenic factors; for injection into pulmonary circulation to locally treat vasculature.

Antigen Express WO 01/21193

Enhancing MHC antigen presentation

Worcester, Mass.

Hybrid polypeptides that enhance MHC Class II antigen presentation; for immune response modulation.

AstraZeneca WO 01/21833

Cystic fibrosis gene alleles


Detection of specific alleles of the human CFTR gene; for diagnosing cystic fibrosis.

Aventis Pasteur WO 01/21802-21806 & 21810

Chlamydia antigens


Chlamydia antigens, encoding gene sequences; for developing diagnostics and therapeutics.

Aventis Pharma WO 01/20977

Alzheimer's model

Antony, France

Animals that show amyloid plaques and mitochondrial dysfunctions; for modeling Alzheimer's.

Aventis Pharma WO 01/21662

Hemostasis therapeutics

Frankfurt, Germany

Signal sequences used for the production of leu-hirudin via secretion by E. coli; for hemostasis therapeutics.

Barnes Jewish Hosp. WO 01/21762

Decreasing cholesterol uptake

St. Louis

Administration of agents that inhibit MDR1; for decreasing cholesterol uptake.

Boehringer Ingelheim Intl. WO 01/22092

Bone disorder therapeutic assay

Ingelheim, Germany

Assays for agents that upregulate osteoblast Fra-1 gene expression; for identifying bone disorder therapeutics.

Brocker, T. WO 01/21199

Dedritic cell DNA vaccination

Horsching, Germany

Highly efficient dendritic cell-targeted DNA vaccination using a promoter active in antigen-presenting cells.

California, Univ. of WO 01/21191

CRF inhibition of cell growth

Oakland, Calif.

Inhibition of abnormal cell growth with corticotropin-releasing factor analogs having D-amino acid moieties.

Cambridge, Univ. of EP 1 088 889

Displaying CTL epitopes

Cambridge, UK

Double hybrid filamentous bacteriophage engineered to display a cytotoxic T cell epitope; for vaccines.

Canbas WO 01/21771

Cell cycle arrest inhibition

Numazu, Japan

Inhibition of Chk1/2 kinases; for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents.

Cedars-Sinai Med. Ctr. WO 01/21649

Estrogen modulator screens

Los Angeles

Genes encoding vitamin D response element binding proteins, encoded proteins; for screening estrogen modulators.

Cell Science Therapeutics WO 01/21766

Non-hematopoietic stem cells

Woburn, Mass.

Methods for isolating non-hematopoietic lineage cells from hematopoietic progenitor cells.

Chugai Res. Inst. Molec. Med. EP 1 088 831

Hemopoietin receptors

Niiheri, Japan

Hemopoietin receptors, modified versions, encoding gene sequences, production methods; for therapeutics.

Chugai Res. Inst. Molec. Med. WO 01/21792

OATP transporter-related proteins

Niiheri, Japan

OATP transporter-related proteins, encoding genes, single nucleotide polymorphisms; for assessing drug therapy.

Cognetix WO 01/21648

Conotoxins for ischemia

Salt Lake City

Use of kappa-conotoxin PVIIA analogs and derivatives to activate ATPase-sensitive potassium channels; for ischemia.

Corixa WO 01/21192

Treating hematologic malignancies


Detecting and treating hematologic and virus-associated malignancies using Her2/neu genes and encoded proteins.

Corixa WO 01/21653

Ovarian tumor antigen


Ovarian tumor antigen, variants, immunogenic fragments, encoding gene sequences; for diagnostics and therapeutics.

Eberhard Karls Univ. WO 01/21789

Restenosis ribozymes

Tubingen, Germany

Ribozymes that target cyclin E or E2F1 mRNAs; for inhibiting smooth muscle cell growth and consequent restenosis.

Epimmune WO 01/21189

Hepatitis immune response

San Diego

Inducing cellular immune responses to hepatitis C virus using viral peptides and encoding nucleic acid sequences.

Forsyth Dental Infirmary WO 01/21797

Osteoclast G-protein regulator


G-protein regulator expressed in osteoclasts, encoding gene sequences; for developing diagnostics and therapeutics.

Fox Chase Cancer Ctr. WO 01/21798

ABCA transporter 2


Human ABCA transporter 2, encoding gene sequences; for developing diagnostics and therapeutics.

Friz Biochem WO 01/21635

Detecting DNA hybridization

Munich, Germany

Methods for electrochemically detecting sequence-specific nucleic acid-oligomer hybridization events.

Genaissance Pharma WO 01/21639

IL-1_ gene SNPs

New Haven, Conn.

Polymorphisms in the interleukin-1_ gene; for defining drug targets.

Gene Logic WO 01/21840

Indexing populations

Gaithersburg, Md.

Methods for using specific gene sequence probes to index populations.

Genetics Inst. WO 01/21796

GL50 proteins

Cambridge, Mass.

GL50 proteins, encoding gene sequences, antisense, transgenics, fusions, antigenic peptides, antibodies.

Genset WO 01/21647

Obesity therapeutics


Methods for screening for compounds that modulate the LSR-leptin interaction; for treating obesity-related diseases.

Genzyme WO 01/21824

Pseudoadenoviral vector production

Cambridge, Mass.

Helper vectors and cell lines for the production of pseudoadenoviral vectors; for gene therapy.

Glaxo WO 01/21791

Stargazin-like polypeptide

Greenford, UK

Stargazin-like polypeptide, encoding gene, variants; for modulating voltage-gated calcium channel activity.

Hitachi Software Engineering EP 1 089 211

Gene expression pattern display

Yokohama, Japan

Methods and apparatus for displaying gene expression patterns; for cluster analysis.

Human Genome Sciences WO 01/21658

32 secreted proteins

Rockville, Md.

32 human secreted proteins, encoding genes, antibodies, production methods; for diagnostics and therapeutics.

Imgenex WO 01/21136

Cancer therapeutic development

San Diego

Antibodies that bind transcription factors; for finding modulators that affect these factors in cancer cells.

Incyte Genomics EP 1 088 890

Recombinant BPI proteins

Palo Alto, Calif.

Recombinant BPI proteins and complexes that have endotoxin neutralizing activity but no bacteriocidal activity.

Incyte Genomics WO 01/21836

Therapeutic genes

Palo Alto, Calif.

Gene sequences for diagnostics and therapeutics, encoded proteins, fragments, oligo probes, gene chips.

Isis Innovation WO 01/21201

Boosting CD8+ cell responses

Summertown, UK

Use of replication-deficient adenoviral vectors to boost CD8+ cell immune responses to antigens.

Isis Innovation WO 01/21655

Bacterial virulence gene

Oxford, UK

Virulence gene from enteric bacteria, encoded protein; for developing antibacterials.

Isis Innovation WO 01/21816

IgE expression modulation

Summertown, UK

Modulation of immunoglobulin E cell surface expression; for modulating allergic reactions.

Isis Innovation WO 01/21832

Diagnosing IBD

Oxford, UK

Diagnosis of inflammatory bowel disease by looking for a 32 base pair deletion in the chemokine receptor CCR5 gene.

Japan Sci. & Technol. WO 01/21788

Mast cell transduction proteins

Saitama, Japan

Mast cell-specific transducing molecules, encoding gene sequences, antibodies; for developing allergy drugs.

Johns Hopkins Univ. WO 01/21652

Correcting protein misfolding


Use of a cell-free system to identify agents that correct defective protein folding.

Karolinska Inst. WO 01/21659

Bone marrow protein

Huddinge, Sweden

Bone marrow protein, encoding gene sequences; for bone disease diagnostics and therapeutics.

Keio Univ. WO 01/21786

Cell death modulation


Methods for screening for proteins that have an effect in diseases associated with cell death.

Keio Univ. WO 01/21787

Neuronal cell death inhibition


Protein that inhibits neuronal cell death associated with Alzheimer's disease, encoding gene sequences.

Kennedy Inst. Rheumatology WO 01/21202

Arthritis therapy


Inhibiting NF-kappaB mediated T cell-induced release of pro-inflammatory cytokines from monocytes; for arthritis.

Kennedy Inst. Rheumatology WO 01/21823

Cytokine controlled vector genes


Adenoviral vectors containing cytokine gene promoters linked to a reporter gene; for studying their cellular expression.

Kennedy Inst. Rheumatology WO 01/21834

Polymorphism assays


Comparison of reporter gene activity linked to distinct promoters in adenoviral vectors; for polymorphism assays.

Leeds, Univ. of WO 01/21780

Targeted transgene removal

Leeds, UK

Removing transgenes with flanking regions of bacteriophage lambda attachment P regions using homologous recombination.

Lexicon Genetics WO 01/21651

Protease inhibitor-like proteins

The Woodlands, Texas

Human protease inhibitor-like proteins, encoding gene sequences; for diagnostics and therapeutics.

Lexicon Genetics WO 01/21773

Endothelin converting enzyme-like proteins

The Woodlands, Texas

Human endothelin converting enzyme-like proteins, encoding genes; for diagnostics and therapeutics.

Linden Technol. WO 01/20998

Finding drug candidates

Woburn, Mass.

Relational databases containing gene expression profiles from various phenotypes; for identifying drug candidates.

Ludwig Inst. Cancer Res. WO 01/21794

Smad-associating proteins

New York

Smad-associating proteins, encoding genes, fragments, functional variants, antibodies; for therapeutics.

Manitoba, Univ. of WO 01/21811

Chlamydia DNA vaccines

Winnipeg, Manitoba

Chlamydia serine-threonine kinase, encoding gene sequences; for DNA immunization against infection.

Mass. Gen. Hosp. WO 01/21837

Potentiating antisense


Potentiating antisense activity by linking antisense to protein-coding gene sequences such as a recombinase gene.

Max Planck Inst. EP 1 088 898

Cancer therapeutics

Munich, Germany

Use of modulators of Rab and Rho GTPases to affect cell cytoskeleton-membrane interactions; for treating cancer.

Mayo Fdn. WO 01/20989

Cancer gene therapy

Rochester, Minn.

Recombinant paramyxoviruses specific for cancers that encode cancer therapeutics; for gene therapy.

McGill Univ. WO 01/21769

Cystic fibrosis therapy


Three-dimensional structure and crystals of a class I endoplasmic reticulum a1,2-mannosidase; for cystic fibrosis.

Medeva EP 1 088 830

Hepatitis B vaccines

Amsterdam, Netherlands

Immunogenic hepatitis B virus antigen particles; for making vaccines.

Medgene Bioscience WO 01/21214

Cerebrovascular gene therapy

Osaka, Japan

Transferring hepatocyte growth factor and VEGF genes into the subarachnoidal space to treat cerebrovascular disorders.

Merck EP 1 088 888

Immunoglobulin Fc fusion

Darmstadt, Germany

Fusion of a signal sequence to an immunoglobulin Fc region that is linked by a target protein; for therapeutics.

Merck WO 01/21814


Darmstadt, Germany

Heparanase-2, encoding gene sequences, recombinant production methods; for diagnostics and therapeutics.

Millennium Pharma WO 01/21631

Secreted proteins

Cambridge, Mass.

Secreted and transmembrane proteins, encoding genes, antibodies; for cancer and immune system therapeutics.

Millennium Pharma WO 01/21641

Immune disorder-related genes

Cambridge, Mass.

Genes differentially expressed in TH1 and TH2 cells; for diagnosing and treating immune system disorders.

Miyasaka, N. WO 01/21793

Arthritis therapy


Use of inhibitors of cyclin-dependent kinases in articular tissues to treat rheumatoid arthritis.

Morphogen Pharma WO 01/21767

Pluripotent embryonic stem cells

Los Angeles

Pluripotent embryonic-like stem cells, isolation methods; for producing lineage-committed cells.

Motorola WO 01/21838

Parallel SNP genotyping

Schaumburg, Ill.

Three-dimensional microarray system for parallel genotyping of single nucleotide polymorphisms.

Netherlands Tech. Develop. Org. WO 01/21200

Oral vaccines

Delft, Netherlands

Recombinant modified Lactobacillus bacteria strains that express antigens; for oral vaccines.

NIH (Natl. Inst. Hlth.) WO 01/21188

Finding serum amyloid ligands

Bethesda, Md.

Assay for identifying serum amyloid ligands using the interaction of this protein with the PPRL 1 receptor.

NIH (Natl. Inst. Hlth.) WO 01/21656

Targeting metalloproteinases

Bethesda, Md.

Mutated anthrax toxin protective antigen proteins that target cells having cell surface metalloproteinases.

NIH (Natl. Inst. Hlth.) WO 01/21807

Hepatitis C vaccines

Bethesda, Md.

Hepatitis C virus envelope protein E2 lacking its hypervariable region, chimeras; for vaccines.

New York, State Univ. of WO 01/21636

E. coli vaccines

Amherst, N.Y.

Cytoplasmic protein from an extraintestinal isolate of E. coli; for developing vaccines.

Novo Nordisk WO 01/21661

Treating thrombosis

Bagsvaerd, Denmark

Bivalent serine protease inhibitor of the Factor VIIa/Xa complex; for treating thrombotic surgical complications.

Pennsylvania, Univ. of WO 01/21640

Sulfatase family


Sulfatase family, encoding genes; for modifying cell growth and preventing lymphocyte recruitment to inflamed tissue.

Pharmacia & Upjohn WO 01/21839

Pathogen gene expression profiles

Kalamazoo, Mich.

Analysis of data generated from microarrays; for developing gene expression profiles of pathogens.

Philadelphia Hlth. & Education WO 01/21828

Cancer marker protein


PCAM-1 cancer marker protein, encoding gene sequences, antibodies; for developing diagnostics and therapeutics.

Pierre Fabre Medicament WO 01/21203

Intranasal vaccines

Boulogne-Billancourt, France

Outer membrane protein A of an enterobacterium associated with an RSV immunogenic peptide; for intranasal vaccines.

Plumley, K.M. EP 1 088 557

Modified p53

Vigo, Spain

In vivo production of antibodies to modified p53; for cancer vaccines.

Prodigene WO 01/21270

Therapeutic proteins from plants

College Stn., Texas

Recovery of recombinant therapeutic proteins from plant tissue; for therapeutic protein production.

Reneuron WO 01/21790

Conditional cell immortalization


Cells having a conditionally-inducible oncogene and a telomerase complex subunit gene; for immortalization.

Rigel Pharma WO 01/21654, 21663, 21784, 21799 & 21815

Cell cycle-related proteins

S. San Francisco

Syk kinase, PCNA, and TRAF4-associated cell cycle proteins, encoding genes, antibodies; for cell cycle control.

Robarts Res. Inst. WO 01/21204

Treating autoimmunity

London, Ont.

Using M3 polypeptide formulations to treat a variety of inflammatory and autoimmune disorders.

Rome Univ. WO 01/21765

Tumor cell killing


Methods for protecting growing normal cells while eradicating tumor cells having an inactive p53 pathway.

Shionogi WO 01/21775

Secretory phospholipase A2

Osaka, Japan

Human secretory phospholipase A2, encoding gene sequences, production methods; for diagnostics and therapeutics.

SmithKline Beecham WO 01/21764

Staphylococcus antibacterials


PCRA helicase of Staphylococcus aureus, encoding gene, recombinant production methods; for antibacterial screens.

Stanford Univ. WO 01/21829

Soluble adenylyl cyclase

Palo Alto, Calif.

Human soluble adenylyl cyclase, encoding gene sequences; for identifying agents for use as male contraceptives.

Suntory WO 01/21205

Coupling factor 6 inhibitor

Osaka, Japan

Inhibitor of coupling factor 6, which is a subunit of a proton-translocating ATPase inhibitor; for therapeutics.

TGT Labs WO 01/21761

Fibrotic disease therapy

Mexico City

Recombinant adenoviral vectors expressing therapeutic proteins that treat various fibrotic diseases.

Vlaams Biotech Inst. EP 1 088 892 & WO 01/21817

Genetically modified pseudovirions

Zwijnaarde, Netherlands

Genetically modified pseudovirions, bacteriophages, or phagemids that enter cells via an artificial receptor.

Whitehead Inst. Biomed. Res. WO 01/21795

Fatty acid transport proteins

Cambridge, Mass.

Fatty acid transport proteins, encoding gene sequences; for developing diagnostics and therapeutics.

York, Univ. of WO 01/21645

Designing antivirals

York, UK

Crystals of an E2 N-terminal module dimmer protein having vital viral transcription residues; for antivirals.

No Comments